Abstract：
Ageing is characterized by a gradual decline in body function, representing the clinical situation called \"frailty\". Prefrailty is the intermediate stage between frailty and robust condition. L-carnitine (LC) plays an important role in energy production from long-chain fatty acids in mitochondria, and its serum level is lower in prefrail and frail subjects.
This study aims to evaluate the effect of Acetyl-L-carnitine (ALCAR) in pre-frail older patients.
We scheduled 3 months of treatment and then 3 months of follow-up. A total of 92 subjects were selected from May, 2009 to July, 2017, in a randomized, observational, double-blind, placebo-controlled study. We scheduled 3 months of treatment and then 3 months of follow-up. ALCAR (oral 1.5 g/bis in die - BID) or placebo groups were used.
After the treatment, only the treated group displayed a decrease in C reactive protein (CRP) p < 0.001 and an increase in serum-free carnitine and acetylcarnitine (p < 0.05) in Mini-Mental state (MMSE) p < 0.0001 and 6-walking distance (p < 0.0001); ALCAR group vs. placebo group showed a decrease in HDL cholesterol and CRP (p < 0.01), an increase in MMSE score (p < 0.001) and in the 6-walking distance (p < 0.001).
ALCAR treatment delays the incidence and severity of onset of degenerative disorders of the elderly in prefrail subjects with improvement in memory and cognitive processes.
This study aims to evaluate the effect of Acetyl-L-carnitine (ALCAR) in pre-frail older patients.
We scheduled 3 months of treatment and then 3 months of follow-up. A total of 92 subjects were selected from May, 2009 to July, 2017, in a randomized, observational, double-blind, placebo-controlled study. We scheduled 3 months of treatment and then 3 months of follow-up. ALCAR (oral 1.5 g/bis in die - BID) or placebo groups were used.
After the treatment, only the treated group displayed a decrease in C reactive protein (CRP) p < 0.001 and an increase in serum-free carnitine and acetylcarnitine (p < 0.05) in Mini-Mental state (MMSE) p < 0.0001 and 6-walking distance (p < 0.0001); ALCAR group vs. placebo group showed a decrease in HDL cholesterol and CRP (p < 0.01), an increase in MMSE score (p < 0.001) and in the 6-walking distance (p < 0.001).
ALCAR treatment delays the incidence and severity of onset of degenerative disorders of the elderly in prefrail subjects with improvement in memory and cognitive processes.
摘要：
衰老的特点是身体机能逐渐下降，代表称为“虚弱”的临床情况。主要是脆弱和稳健状态之间的中间阶段。左旋肉碱(LC)在线粒体中长链脂肪酸产生能量的过程中发挥重要作用,在脆弱前和虚弱的受试者中，其血清水平较低。
本研究旨在评估乙酰-L-肉碱（ALCAR）在体弱前期老年患者中的作用。
我们安排了3个月的治疗和3个月的随访。从5月共选取92名受试者,2009年7月,2017年，在一个随机的，观察,双盲,安慰剂对照研究。我们安排了3个月的治疗和3个月的随访。使用ALCAR(口服1.5g/bis,在die-BID中)或安慰剂组。
治疗后，仅治疗组表现出C反应蛋白（CRP）p<0.001降低，而无血清肉碱和乙酰肉碱（p<0.05）在迷你精神状态（MMSE）p<0.0001和6步行距离（p<0.0001）中增加；ALCAR组vs.安慰剂组显示HDL胆固醇和CRP降低（p<0.01），MMSE评分（p<0.001）和6步行距离（p<0.001）的增加。
ALCAR治疗延缓了老年患者退行性疾病的发病率和严重程度，改善了记忆和认知过程。
本研究旨在评估乙酰-L-肉碱（ALCAR）在体弱前期老年患者中的作用。
我们安排了3个月的治疗和3个月的随访。从5月共选取92名受试者,2009年7月,2017年，在一个随机的，观察,双盲,安慰剂对照研究。我们安排了3个月的治疗和3个月的随访。使用ALCAR(口服1.5g/bis,在die-BID中)或安慰剂组。
治疗后，仅治疗组表现出C反应蛋白（CRP）p<0.001降低，而无血清肉碱和乙酰肉碱（p<0.05）在迷你精神状态（MMSE）p<0.0001和6步行距离（p<0.0001）中增加；ALCAR组vs.安慰剂组显示HDL胆固醇和CRP降低（p<0.01），MMSE评分（p<0.001）和6步行距离（p<0.001）的增加。
ALCAR治疗延缓了老年患者退行性疾病的发病率和严重程度，改善了记忆和认知过程。
